Data gathered: October 23
Alternative Data for Amgen
About Amgen
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
| Price | $292.89 |
| Target Price | Sign up |
| Volume | 1,500,000 |
| Market Cap | $162B |
| Year Range | $257.92 - $321.92 |
| Dividend Yield | 3.05% |
| PE Ratio | 24.64 |
| Analyst Rating | 53% buy |
| Earnings Date | November 4 '25 |
| Industry | Biotechnology |
In the news
 |
2 Reasons to Like AMGN and 1 to Stay SkepticalOctober 19 - Yahoo |
 |
US FDA expands use of Amgen, AstraZeneca's drug for sinus infectionOctober 17 - Biztoc.com |
 |
Price Over Earnings Overview: AmgenOctober 17 - Biztoc.com |
Amgen Inc. stock outperforms competitors on strong trading dayOctober 17 - MarketWatch |
|
FDA Approves Amgen and AstraZeneca Treatment for Nasal Polyps ConditionOctober 17 - MarketWatch |
|
|
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking TherapeuticsOctober 16 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 9.17B | 3.01B | 6.16B | 1.43B | 3.62B | 6.020 |
| Q1 '25 | 8.15B | 2.97B | 5.18B | 1.73B | 4.08B | 4.900 |
| Q4 '24 | 9.09B | 3.11B | 5.97B | 627M | 2.93B | 5.310 |
| Q3 '24 | 8.5B | 3.31B | 5.19B | 2.83B | 5.27B | 5.580 |
| Q2 '24 | 8.39B | 3.24B | 5.15B | 746M | 3B | 4.970 |
Insider Transactions View All
| Grygiel Nancy A. filed to sell 7,209 shares at $297. August 22 '25 |
| Khosla Rachna filed to sell 8,162 shares at $289.7. June 6 '25 |
| Busch Matthew C. filed to sell 4,034 shares at $279.7. May 6 '25 |
| REESE DAVID M filed to sell 36,922 shares at $304.4. February 21 '25 |
| Miller Derek filed to sell 8,544 shares at $293.7. February 20 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Marjorie Taylor Greene |
Sep 29, 25 | Buy | $1K - $15K |
| Daniel Meuser |
Aug 21, 25 | Sell | $1K - $15K |
| Lisa McClain |
Aug 13, 25 | Buy | $1K - $15K |
Read more about Amgen (AMGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Amgen?
The Market Cap of Amgen is $162B.
What is Amgen's PE Ratio?
As of today, Amgen's PE (Price to Earnings) ratio is 24.64.
When does Amgen report earnings?
Amgen will report its next earnings on November 4 '25.
What is the current stock price of Amgen?
Currently, the price of one share of Amgen stock is $292.89.
How can I analyze the AMGN stock price chart for investment decisions?
The AMGN stock price chart above provides a comprehensive visual representation of Amgen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amgen shares. Our platform offers an up-to-date AMGN stock price chart, along with technical data analysis and alternative data insights.
Does AMGN offer dividends to its shareholders?
Yes, Amgen (AMGN) offers dividends to its shareholders, with a dividend yield of 3.05%. This dividend yield represents Amgen's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Amgen in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Amgen?
Some of the similar stocks of Amgen are Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.
